Search Results - "STEWART, Keith"

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma by Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith E., Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Philippe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, Morgan, Gareth J.

“…Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can…”
Get full text

Carfilzomib by Kortuem, K. Martin, Stewart, A. Keith

“…This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for…”
Get full text

How Thalidomide Works Against Cancer by Stewart, A. Keith

“…The surprising ability of thalidomide and its analogs to treat various hematologic malignancies is through the loss of two transcription factors. [Also see…”
Get full text

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide by Zhu, Yuan Xiao, Braggio, Esteban, Shi, Chang-Xin, Bruins, Laura A., Schmidt, Jessica E., Van Wier, Scott, Chang, Xiu-Bao, Bjorklund, Chad C., Fonseca, Rafael, Bergsagel, P. Leif, Orlowski, Robert Z., Stewart, A. Keith

“…The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects…”
Get full text

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation by PALUMBO, Antonio, VINCENT RAJKUMAR, S, DIMOPOULOS, Meletios A, RICHARDSON, Paul G, CAVO, Michele, SPENCER, Andrew, KEITH STEWART, A, SHIMIZU, Kazuyuki, LONIAL, Sagar, SONNEVELD, Pieter, DURIE, Brian G. M, MOREAU, Philippe, SAN MIGUEL, Jesus F, ORLOWSKI, Robert Z, LAROCCA, Alessandra, NIESVIZKY, Ruben, MORGAN, Gareth, LANDGREN, Ola, HAJEK, Roman, EINSELE, Hermann, ANDERSON, Kenneth C

“…To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. A…”
Get full text

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma by Leung-Hagesteijn, Chungyee, Erdmann, Natalie, Cheung, Grace, Keats, Jonathan J., Stewart, A. Keith, Reece, Donna E., Chung, Kim Chan, Tiedemann, Rodger E.

“…Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial. We report the existence of a progenitor organization in primary…”
Get full text

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis by Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith, Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Phillipe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, Morgan, Gareth

“…Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple…”
Get full text

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma by Zhu, Yuan Xiao, Kortuem, K. Martin, Stewart, A. Keith

“…Abstract Although several mechanisms have been proposed to explain the activity of thalidomide, lenalidomide and pomalidomide in multiple myeloma (MM),…”
Get full text

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma by Siegel, David S., Martin, Thomas, Wang, Michael, Vij, Ravi, Jakubowiak, Andrzej J., Lonial, Sagar, Trudel, Suzanne, Kukreti, Vishal, Bahlis, Nizar, Alsina, Melissa, Chanan-Khan, Asher, Buadi, Francis, Reu, Frederic J., Somlo, George, Zonder, Jeffrey, Song, Kevin, Stewart, A. Keith, Stadtmauer, Edward, Kunkel, Lori, Wear, Sandra, Wong, Alvin F., Orlowski, Robert Z., Jagannath, Sundar

“…Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this…”
Get full text

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Palumbo, Antonio, Bringhen, Sara, Mateos, Maria-Victoria, Larocca, Alessandra, Facon, Thierry, Kumar, Shaji K., Offidani, Massimo, McCarthy, Philip, Evangelista, Andrea, Lonial, Sagar, Zweegman, Sonja, Musto, Pellegrino, Terpos, Evangelos, Belch, Andrew, Hajek, Roman, Ludwig, Heinz, Stewart, A. Keith, Moreau, Philippe, Anderson, Kenneth, Einsele, Hermann, Durie, Brian.G.M., Dimopoulos, Meletios A., Landgren, Ola, San Miguel, Jesus F., Richardson, Paul, Sonneveld, Pieter, Rajkumar, S. Vincent

“…We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from 3 prospective trials. At diagnosis, a geriatric assessment had been…”
Get full text

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma by Lazzari, Elisa, Mondala, Phoebe K., Santos, Nathaniel Delos, Miller, Amber C., Pineda, Gabriel, Jiang, Qingfei, Leu, Heather, Ali, Shawn A., Ganesan, Anusha-Preethi, Wu, Christina N., Costello, Caitlin, Minden, Mark, Chiaramonte, Raffaella, Stewart, A.  Keith, Crews, Leslie A., Jamieson, Catriona H. M.

“…Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive…”
Get full text

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma by Stewart, A. Keith, Rajkumar, S. Vincent, Dimopoulos, Meletios A, Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David S, Mihaylov, Georgi G, Goranova-Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej J, San-Miguel, Jesus F, Ludwig, Heinz, Wang, Michael, Maisnar, Vladimír, Minarik, Jiri, Bensinger, William I, Mateos, Maria-Victoria, Ben-Yehuda, Dina, Kukreti, Vishal, Zojwalla, Naseem, Tonda, Margaret E, Yang, Xinqun, Xing, Biao, Moreau, Philippe, Palumbo, Antonio

“…In this study, the addition of carfilzomib to lenalidomide and dexamethasone improved response rates and overall survival among patients with relapsed multiple…”
Get full text

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis by Mikhael, Joseph R., Schuster, Steven R., Jimenez-Zepeda, Victor H., Bello, Nancy, Spong, Jacy, Reeder, Craig B., Stewart, A. Keith, Bergsagel, P. Leif, Fonseca, Rafael

“…Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before…”
Get full text

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma by Vogl, Dan T, Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L, Costa, Luciano J, Kaminetzky, David, Hoffman, James E, Yee, Andrew J, Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D, Choe-Juliak, Cassandra, Stewart, A Keith

“…Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor…”
Get full text

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2 by Munshi, Nikhil C., Anderson, Kenneth C., Bergsagel, P. Leif, Shaughnessy, John, Palumbo, Antonio, Durie, Brian, Fonseca, Rafael, Stewart, A. Keith, Harousseau, Jean-Luc, Dimopoulos, Meletios, Jagannath, Sundar, Hajek, Roman, Sezer, Orhan, Kyle, Robert, Sonneveld, Pieter, Cavo, Michele, Rajkumar, S. Vincent, San Miguel, Jesus, Crowley, John, Avet-Loiseau, Hervé

“…A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk…”
Get full text

The inflammatory microenvironment in colorectal neoplasia by McLean, Mairi H, Murray, Graeme I, Stewart, Keith N, Norrie, Gillian, Mayer, Claus, Hold, Georgina L, Thomson, John, Fyfe, Nicky, Hope, Mairi, Mowat, N Ashley G, Drew, Janice E, El-Omar, Emad M

“…Colorectal cancer (CRC) is a major cause of mortality and morbidity worldwide. Inflammatory activity within the stroma of invasive colorectal tumours is known…”
Get full text

Loss of FAM46C Promotes Cell Survival in Myeloma by Zhu, Yuan Xiao, Shi, Chang-Xin, Bruins, Laura A, Jedlowski, Patrick, Wang, Xuewei, Kortüm, K Martin, Luo, Moulun, Ahmann, Jonathan M, Braggio, Esteban, Stewart, A Keith

“…is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that…”
Get full text

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes by Kortüm, K.Martin, Mai, Elias K., Hanafiah, Nur H., Shi, Chang-Xi, Zhu, Yuan-Xiao, Bruins, Laura, Barrio, Santiago, Jedlowski, Patrick, Merz, Maximilian, Xu, Jing, Stewart, Robert A., Andrulis, Mindaugas, Jauch, Anna, Hillengass, Jens, Goldschmidt, Hartmut, Bergsagel, P.Leif, Braggio, Esteban, Stewart, A.Keith, Raab, Marc S.

“…In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM) patients was performed by using the Multiple Myeloma Mutation…”
Get full text

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 by Mikhael, Joseph R., MD, Dingli, David, MD, PhD, Roy, Vivek, MD, Reeder, Craig B., MD, Buadi, Francis K., MD, Hayman, Suzanne R., MD, Dispenzieri, Angela, MD, Fonseca, Rafael, MD, Sher, Taimur, MD, Kyle, Robert A., MD, Lin, Yi, MD, PhD, Russell, Stephen J., MD, PhD, Kumar, Shaji, MD, Bergsagel, P. Leif, MD, Zeldenrust, Steven R., MD, PhD, Leung, Nelson, MD, Drake, Matthew T., MD, PhD, Kapoor, Prashant, MD, Ansell, Stephen M., MD, PhD, Witzig, Thomas E., MD, Lust, John A., MD, PhD, Dalton, Robert J., MD, Gertz, Morie A., MD, Stewart, Keith, MBChB, Rajkumar, S. Vincent, MD, Chanan-Khan, Asher, MD, Lacy, Martha Q., MD

“…Abstract Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. There has been a…”
Get full text

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome by TIEDEMANN, Rodger E, YUAN XAO ZHU, SCHMIDT, Jessica, CHANG XIN SHI, SEREDUK, Chris, HONGWEI YIN, MOUSSES, Spyro, KEITH STEWART, A

“…Despite recent advances in targeted treatments for multiple myeloma, optimal molecular therapeutic targets have yet to be identified. To functionally identify…”
Get full text